Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
   Or select

Or become a subscriber

RabMAbs as an Alternative Source of Therapeutic Leads

Properties such as high binding affinity and specificity, the ability to recognise novel epitopes and ease of humanisation make rabbit monoclonal antibodies (RabMAbs) an attractive target for the development of therapeutic antibodies.

By Guo-Liang Yu at Epitomics, Inc (March 2010)

Keywords: RabMAbs, alternative, therapeutic leads, novel epitopes, rabbid monoclonal antibodies, platforms, high binding affinity, surrogate antibody, humanising

    View full article    |    Back to Biopharma section

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |